Tiagabine
Based on 1 Customer Validation
Tiagabine (NO050328; NO328; TGB) is an orally active, highly selective, and reversible GAT-1 inhibitor and anticonvulsant that crosses the blood-brain barrier. By blocking the reuptake of GABA in neurons and glial cells, tiagabine increases extracellular GABA levels to enhance inhibitory signal transduction, thereby exerting multiple activities such as anticonvulsant, neuroprotective, and antioxidant effects. Tiagabine exhibits linear pharmacokinetic properties. Although it is metabolized by CYP3A and has a high protein binding rate, it carries a low risk of cognitive impairment. Tiagabine is widely used in research on related diseases including epilepsy (including refractory partial seizures), alcohol withdrawal symptoms, and Huntington's disease.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 99.20%
- CAS No.: 115103-54-3
- Formule: C20H25NO2S2
- Masse moléculaire:375.55
-
Stockage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
-
Solvant et solubilité
- Pureté et documentation
- Références
-
Help & FAQs
-
Membrane Transporter/Ion Channel Compound Library
HY-L011
-
Neuronal Signaling Compound Library
HY-L013
-
FDA-Approved Drug Library
HY-L022
-
CNS-Penetrant Compound Library
HY-L028
-
Drug Repurposing Compound Library
HY-L035
-
Antioxidant Compound Library
HY-L037
-
Orally Active Compound Library
HY-L061
-
Neurotransmitter Receptor Compound Library
HY-L062
-
FDA Approved & Pharmacopeial Drug Library
HY-L066
-
Anti-Alzheimer's Disease Compound Library
HY-L069
-
Neuroprotective Compound Library
HY-L070
-
Anti-Parkinson's Disease Compound Library
HY-L085
-
Neurodegenerative Disease-related Compound Library
HY-L086
-
GABA Receptor Compound Library
HY-L120
-
Human Metabolite Library
HY-L123
-
Off-patent Drug Library
HY-L141
-
Membrane Protein-targeted Compound Library
HY-L149
-
Membrane Receptor-targeted Compound Library
HY-L150
-
Highly Selective Inhibitors Library
HY-L158
-
Ion Channel Compound Library
HY-L166
-
Radioprotector Library
HY-L178
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Drug Repurposing Compound Library Plus
HY-L035P
-
FDA-Approved Drug Library Plus
HY-L022P
-
FDA-Approved Drug Library Mini
HY-L022M
-
Bioactive Compound Library
HY-L001
-
Anti-Fibrosis Compound Library
HY-L185
-
High-Throughput Bioactive Compound Library
HY-L205
-
Mass Spectrometry Human Metabolite Library
HY-L215
-
Nephrotoxicity Compound Library
HY-L229
Activité biologique
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| HEK293 | IC50 |
>300 μM
Compound: (R)-1a
|
Inhibition of mouse mGAT3 expressed in HEK293 cells assessed as inhibition of [3H]GABA uptake after 3 mins incubation by TopCount microplate scintillation counting analysis
Inhibition of mouse mGAT3 expressed in HEK293 cells assessed as inhibition of [3H]GABA uptake after 3 mins incubation by TopCount microplate scintillation counting analysis
|
[PMID: 25882526] |
| HEK293 | IC50 |
>300 μM
Compound: 1, Tiagabine
|
Inhibition of [3H]GABA uptake at mouse GAT3 expressed in HEK293 cells after 3 mins by scintillation counting analysis
Inhibition of [3H]GABA uptake at mouse GAT3 expressed in HEK293 cells after 3 mins by scintillation counting analysis
|
[PMID: 23398473] |
| HEK293 | IC50 |
0.07 μM
Compound: 5
|
Inhibition of [3H]GABA uptake at mouse GAT1 expressed in HEK293 cells after 25 mins by scintillation counting analysis
Inhibition of [3H]GABA uptake at mouse GAT1 expressed in HEK293 cells after 25 mins by scintillation counting analysis
|
[PMID: 23336362] |
| HEK293 | IC50 |
0.64 μM
Compound: 5
|
Inhibition of rat GAT1 expressed in HEK293 cells assessed as inhibition of [3H]GABA uptake by liquid scintillation counting
Inhibition of rat GAT1 expressed in HEK293 cells assessed as inhibition of [3H]GABA uptake by liquid scintillation counting
|
[PMID: 25679268] |
| HEK293 | IC50 |
0.8 μM
Compound: (R)-1a
|
Inhibition of mouse mGAT1 expressed in HEK293 cells assessed as inhibition of [3H]GABA uptake after 3 mins incubation by TopCount microplate scintillation counting analysis
Inhibition of mouse mGAT1 expressed in HEK293 cells assessed as inhibition of [3H]GABA uptake after 3 mins incubation by TopCount microplate scintillation counting analysis
|
[PMID: 25882526] |
| HEK293 | IC50 |
0.8 μM
Compound: 1, Tiagabine
|
Inhibition of [3H]GABA uptake at mouse GAT1 expressed in HEK293 cells after 3 mins by scintillation counting analysis
Inhibition of [3H]GABA uptake at mouse GAT1 expressed in HEK293 cells after 3 mins by scintillation counting analysis
|
[PMID: 23398473] |
| HEK293 | IC50 |
300 μM
Compound: (R)-1a
|
Inhibition of mouse mGAT2 expressed in HEK293 cells assessed as inhibition of [3H]GABA uptake after 3 mins incubation by TopCount microplate scintillation counting analysis
Inhibition of mouse mGAT2 expressed in HEK293 cells assessed as inhibition of [3H]GABA uptake after 3 mins incubation by TopCount microplate scintillation counting analysis
|
[PMID: 25882526] |
| HEK293 | IC50 |
300 μM
Compound: 1, Tiagabine
|
Inhibition of [3H]GABA uptake at mouse GAT2 expressed in HEK293 cells after 3 mins by scintillation counting analysis
Inhibition of [3H]GABA uptake at mouse GAT2 expressed in HEK293 cells after 3 mins by scintillation counting analysis
|
[PMID: 23398473] |
| HEK293 | IC50 |
800 μM
Compound: (R)-1a
|
Inhibition of mouse mGAT4 expressed in HEK293 cells assessed as inhibition of [3H]GABA uptake after 3 mins incubation by TopCount microplate scintillation counting analysis
Inhibition of mouse mGAT4 expressed in HEK293 cells assessed as inhibition of [3H]GABA uptake after 3 mins incubation by TopCount microplate scintillation counting analysis
|
[PMID: 25882526] |
| HEK293 | IC50 |
800 μM
Compound: 1, Tiagabine
|
Inhibition of [3H]GABA uptake at mouse GAT4 expressed in HEK293 cells after 3 mins by scintillation counting analysis
Inhibition of [3H]GABA uptake at mouse GAT4 expressed in HEK293 cells after 3 mins by scintillation counting analysis
|
[PMID: 23398473] |
Tiagabine (0.1-5 μM; 4 days) protects Tet-off PC12 cells expressing mutant huntingtin against toxicity, with significant effects detected at concentrations of 0.5, 2, and 5 μM after 4 days of treatment[1].
Tiagabine potently and selectively inhibits GABA uptake in glial, neuronal, and synaptosomal preparations, with IC50 values of 0.18 μmol/L, 0.45 μmol/L, and 0.07 μmol/L, respectively[3].
Tiagabine (2-100 μM; 5-15 min) induces long-lasting, repetitive slow depolarizations in cortical wedges from 20-30 day-old DBA/2 mice, with consistent amplitude and frequency across tested concentrations of 2, 5, 50, and 100 μM following 15-min perfusion, and following shorter 5-10 min perfusions of 50 μM[4].
Tiagabine (50 μM; 15 min)-induced depolarizations in cortical wedges from 20-30 day-old DBA/2 mice are Ca2+-dependent, mediated via GABAA receptors, require voltage-dependent sodium channel activity, are unaffected by NMDA receptor blockade, are partially inhibited by AMPA receptor blockade, are abolished by Dextromethorphan, and are potentiated by potassium channel blockade[4].
Tiagabine (50 μM; 15 min) induces depolarizations in cortical wedges from 50 day-old DBAr2 mice and BALB/c mice, similar to responses in 20-30 day-old DBAr2 mice[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:Tet-off PC12 cells expressing mutant huntingtin (htt-N63-148Q)
-
Concentration:0.1, 0.5, 1, 2, 5 μM
-
Incubation Time:4 days
-
Result:Inhibited LDH release induced by mutant htt in a concentration-dependent manner.
Showed statistically significant reductions in LDH release at 0.5, 2, and 5 μM compared to untreated mutant htt-expressing cells.
| Species | Dose | Route | Serum Concentration | Brain Concentration |
|---|---|---|---|---|
| Mice[1] | 5 mg/kg | i.p. | 17.2 ± 4.8 ng/mL | 177.0 ± 14.2 ng/mL |
Tiagabine (5 mg/kg; i.p.; daily; lifelong administration) extends the survival of male and female R6/2 transgenic Huntington's disease mice (17.8 days of extension at the dose of 5 mg/kg), improves their motor function, and alleviates brain atrophy[1].
Tiagabine (0.4 mg/kg; i.p.; single administration; 30 min prior to seizure testing) exerts a protective effect against audiogenic tonic seizures in male DBA/2 mice, with an ED50 of 0.4 mg/kg[2].
Tiagabine (1.2-1.3 mg/kg; i.p.; single administration; 30 min prior to seizure tests) exerts a protective effect against PTZ-induced tonic convulsions in male NMRI mice, with an ED50 of 1.2 mg/kg, while providing approximately 50% partial protection against clonic convulsions[2].
Tiagabine (15-30 mg/kg; p.o.; twice daily; for consecutive 21 days) induces tolerance to cognitive effects in mice, but does not induce tolerance to its anticonvulsant effects in DMCM-induced epileptic mice[3].
Tiagabine (9 mg/kg; subcutaneous injection; once daily for 8 consecutive days; single injection 30 min prior to locomotor activity test) initially reduces short-term spontaneous ethanol intake in ad libitum-fed C57BL/6 mice, but tolerance develops rapidly, resulting in ethanol intake exceeding pre-treatment levels on days 7-8[5].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:R6/2 mice with Huntington's disease (male, female; CBA/C57Bl6 background; CAG repeat length 110-118; Huntington's disease transgenic model)[1]
-
Dosage:5 mg/kg
-
Administration:i.p.; daily; lifelong
-
Result:Increased average survival to 102.0 ± 2.9 days compared to 84.2 ± 3.5 days in vehicle controls.
Improved rotarod performance at 10 and 12 weeks of age with statistically significant increases in time on the rod relative to vehicle-treated mice.
Increased striatal volume and reduced lateral ventricle volume relative to vehicle-treated mice, attenuating brain atrophy.
Showed no effect on the number of huntingtin aggregates in the frontal cortex or striatum, and did not affect body weight loss in HD mice.
-
Animal Model:C57BL/6 mice with Alcohol use disorder (male, initially 7 weeks old, food-restricted to 80% of ad libitum body weight)[5]
-
Dosage:1 mg/kg; 3 mg/kg; 6 mg/kg; 9 mg/kg
-
Administration:s.c.; single injection 30 minutes prior to test; daily for 13 days; single injection 30 minutes prior to post-prandial test
-
Result:Produced dose-responsive reductions in lever responses, fountain contacts, and ethanol intake during pre-prandial testing.
Significantly reduced all three measures at 6 mg/kg and 9 mg/kg doses compared to saline.
Reduced lever responses across 13 days of daily 9 mg/kg administration with no evidence of tolerance.
Developed tolerance to the reduction of fountain contacts by the second week of 9 mg/kg daily treatment.
Reduced lever responses at 6 mg/kg, and reduced lever responses, fountain contacts, and ethanol intake at 9 mg/kg during post-prandial testing compared to saline.
Reduced lever responses for ethanol by 43% at 9 mg/kg, a significantly greater reduction than the 26% reduction observed for water.
Reduced motor activity by ~45% on the first day of 9 mg/kg administration, but tolerance to this sedative effect developed by the third daily injection.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 115103-54-3
-
Appearance Solid
-
Masse moléculaire 375.55
-
Formule C20H25NO2S2
-
Color Off-white to light yellow
-
SMILES
O=C([C@H]1CN(CC/C=C(C2=C(C)C=CS2)/C3=C(C)C=CS3)CCC1)O
-
Synonyms
NO050328; NO328; TGB
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Solvant et solubilité
DMSO : 100 mg/mL (266.28 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (6.66 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (6.66 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Pureté et documentation
-
Fiche technique (281 KB)
-
SDS (396 KB)
- English - EN (396 KB)
- Français - FR (396 KB)
- Deutsch - DE (396 KB)
- Norwegian - NO (396 KB)
- Español - ES (396 KB)
- Swedish - SV (396 KB)
- Italian - IT (396 KB)
- Korean - KR (396 KB)
- Portuguese - PT (396 KB)
-
Instruction de manipulation (2659 KB)
Références
[2]. Nielsen EB, et al. Characterization of tiagabine (NO-328), a new potent and selective GABA uptake inhibitor. Eur J Pharmacol. 1991;196(3):257-266. [Content Brief]
[4]. Hu RQ, et al. Tigabine hydrochloride, an inhibitor of gamma-aminobutyric acid (GABA) uptake, induces cortical depolarizations in vitro. Brain Res. 1997;753(2):260-268. [Content Brief]
[5]. Nguyen SA, et al. Tiagabine reduces ethanol reward in C57BL/6 mice under acute and chronic administration regimens. Synapse. 2005;56(3):135-146. [Content Brief]
[6]. Javaid S, et al. Tiagabine suppresses pentylenetetrazole-induced seizures in mice and improves behavioral and cognitive parameters by modulating BDNF/TrkB expression and neuroinflammatory markers. Biomed Pharmacother. 2023;160:114406. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.6628 mL | 13.3138 mL | 26.6276 mL | 66.5690 mL |
| 5 mM | 0.5326 mL | 2.6628 mL | 5.3255 mL | 13.3138 mL | |
| 10 mM | 0.2663 mL | 1.3314 mL | 2.6628 mL | 6.6569 mL | |
| 15 mM | 0.1775 mL | 0.8876 mL | 1.7752 mL | 4.4379 mL | |
| 20 mM | 0.1331 mL | 0.6657 mL | 1.3314 mL | 3.3285 mL | |
| 25 mM | 0.1065 mL | 0.5326 mL | 1.0651 mL | 2.6628 mL | |
| 30 mM | 0.0888 mL | 0.4438 mL | 0.8876 mL | 2.2190 mL | |
| 40 mM | 0.0666 mL | 0.3328 mL | 0.6657 mL | 1.6642 mL | |
| 50 mM | 0.0533 mL | 0.2663 mL | 0.5326 mL | 1.3314 mL | |
| 60 mM | 0.0444 mL | 0.2219 mL | 0.4438 mL | 1.1095 mL | |
| 80 mM | 0.0333 mL | 0.1664 mL | 0.3328 mL | 0.8321 mL | |
| 100 mM | 0.0266 mL | 0.1331 mL | 0.2663 mL | 0.6657 mL |
Tiagabine Related Classifications
HY-B0696 Related Classifications
Powered by Bioz